The Clinical Observation On The Effect Of Prescription For FuHeBeiHua Combined With TACE Treatment Of Hepatic Stagnation And Spleen Deficiency Type Of Primary Liver Cancer

Objective:To observe and compare results from studies conducted using methods of treatment with TACE alone,including assessing the effects from prescribed FuHeBeiHua combined with the administration of TACE via biomarkers,and to acquire proficiency of short-term productivity in efficacy and safety of patients diagnosed with Hepatic stagnation and spleen deficiency types of primary liver cancers that have reached middle or advanced stages(stage ?b,?a,& ?b).Method:Through a randomized and controlled clinical trial;100 patients diagnosed with Hepatocellular Carcinoma whom conformed to the standard of case selection,they were then randomly divided into a experimental group and a control group containing 50 patients within each group.The patients in the experimental group were prescribed with FuHeBeiHua combined with TACE,whilst the control group were administered TACE alone.The plasma VEGF/PDGF-AB expression levels,short-term efficacy,TCM symptoms score,Progress Free Survival,serum AFP expression level,KPS score and adverse reactions of the two groups of patients were observed and then compared extensively.Results:(1)The VEGF level: VEGF expression levels attained from assessments of the control group subjects decreased and then increased(P<0.05),while VEGF expression levels extracted from the experimental group continued to decrease(P<0.05),and results at rate of suppression of cancerous cells were significantly better than the control group three months after TACE(P <0.05).(2)The PDGF-AB level: PDGF-AB expression levels in both groups increased and eventually decreased(P<0.05),but the experimental group had shown results significantly superior than the control group in three months after TACE(P<0.05).(3)The short-term efficacy: The objective response rate for the experimental group was 28.26% and disease control rate was 84.87% whilst the extracted results of the control group showed an Objective response rate of 22.73% and disease control rate of 79.55%.There were no significant difference between the two groups(P>0.05)but the best overall response rate could not be determined within both groups due to the lack of significant difference and short study length of subjects.(4)TCM symptoms score: Both groups had improved in results for total score of TCM symptoms;(P < 0.05),the total effective rate of the experimental group was 73.91%,and the control group was 27.27%.The experimental group shown a TCM symptom score significantly higher than the control group including the results concluded from the evaluation of curative effect(P<0.05).(5)PFS: The median PFS was 5.7+ months in the experimental group and 5.0-months in the control group,there were no significant difference in PFS results between the two groups(P>0.05).(6)AFP level: Both group results implied a down-regulation of AFPexpression level after TACE(P < 0.05),and there were no significant differences between the two groups at all;from pre-study and post-study(P>0.05).(7)KPS score: Both groups had improved in their KPS score 3 months after the administration of TACE(P < 0.05);the effective rate of the experimental group was 54.35%,and that of the control group was 25.00%respectively.The stable rate of the experimental group was 93.48%,but that of the control group was at 79.55%.The experimental group resulted in a stabilization and effectual rate noticeably better than the control group(P<0.05).(8)Safety: There were no serious adverse reactions(including negative symptoms)that were related to the study that occurred,and no significant difference in the results of laboratory examination from tissue and cell samples extracted before and after TACE in either group subjects.The results and recovery scores from the experimental group were evidently better than the control group;related to the adverse reaction of fever(P<0.05).Conclusion:Compared to the use of TACE alone in the attempt of treatment of patients with Hepatic stagnation and spleen deficiency type of primary liver cancer in middle and advanced stage;a prescription for FuHeBeiHua combined with TACE can effectively improve TCM syndromes,quality of life,and prevention rate;it is a safe and effective method of treatment.The combined prescription can also down-regulate the expression levels of plasma VEGF and PDGF-AB in 3 mouths after the administration of TACE,so a further study is to be considered and may further produce an innovative path within cancer treatment including cancer research.